| Honeylette Sy Wong, NP | |
|
540 W Pueblo St, Santa Barbara, CA 93105 | |
| (805) 563-5800 | |
| Not Available |
| Full Name | Honeylette Sy Wong |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Acute Care |
| Location | 540 W Pueblo St, Santa Barbara, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073169736 | NPI | - | NPPES |
| NP95012719 | Other | CA | MEDICAL LICENCE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 719117 (California) | Secondary |
| 363LA2100X | Nurse Practitioner - Acute Care | NP95012719 (California) | Primary |
| Entity Name | Sansum Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154354504 PECOS PAC ID: 3678471976 Enrollment ID: O20031223000607 |
News Archive
Covance Inc. announced today it entered into an accelerated share repurchase transaction with JPMorgan Chase Bank. Covance will repurchase shares of its common stock pursuant to the ASR Agreement as part of the $250 million share repurchase program that it announced on September 28, 2010.
YM BioSciences Inc. today announced that preliminary results of a Phase II study evaluating the safety and efficacy of nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG) were reported at the 43rd Congress of the International Society of Paediatric Oncology (SIOP) conference being held in Auckland, New Zealand.
The Bureau of Investigative Journalism examines what some experts are calling a serious inequity in public health spending, writing that neglected tropical diseases (NTDs) "together kill more people than maternal mortality and have a higher disease burden than malaria or tuberculosis (TB) and nearing that of HIV/AIDS. However, despite the severity of the situation, funding for NTDs is just a fraction of that spent on other diseases."
A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D. of NYU Langone Medical Center, lead author of a recent study published online ahead of print in the Journal of Clinical Oncology.
DARA BioSciences, provided additional details from the recently completed Phase I clinical study for DB959, its PPAR delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Honeylette Sy Wong, NP Po Box 62106, Santa Barbara, CA 93160-2106 Ph: (805) 563-5800 | Honeylette Sy Wong, NP 540 W Pueblo St, Santa Barbara, CA 93105 Ph: (805) 563-5800 |
News Archive
Covance Inc. announced today it entered into an accelerated share repurchase transaction with JPMorgan Chase Bank. Covance will repurchase shares of its common stock pursuant to the ASR Agreement as part of the $250 million share repurchase program that it announced on September 28, 2010.
YM BioSciences Inc. today announced that preliminary results of a Phase II study evaluating the safety and efficacy of nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG) were reported at the 43rd Congress of the International Society of Paediatric Oncology (SIOP) conference being held in Auckland, New Zealand.
The Bureau of Investigative Journalism examines what some experts are calling a serious inequity in public health spending, writing that neglected tropical diseases (NTDs) "together kill more people than maternal mortality and have a higher disease burden than malaria or tuberculosis (TB) and nearing that of HIV/AIDS. However, despite the severity of the situation, funding for NTDs is just a fraction of that spent on other diseases."
A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D. of NYU Langone Medical Center, lead author of a recent study published online ahead of print in the Journal of Clinical Oncology.
DARA BioSciences, provided additional details from the recently completed Phase I clinical study for DB959, its PPAR delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes.
› Verified 6 days ago
Erica Gallen, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 517 W Junipero St, Santa Barbara, CA 93105 Phone: 805-979-4650 Fax: 805-685-2802 | |
Michelle L Meinzer, N.P. Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 215 Pesetas Ln, Santa Barbara, CA 93110 Phone: 805-681-1761 Fax: 805-681-1768 | |
Cara Spieler, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 315 Camino Del Remedio, Santa Barbara, CA 93110 Phone: 805-681-5244 | |
Ms. Marjorie Wasem Nilson, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: Student Health Service, University Of California, Santa Barbara, Santa Barbara, CA 93106 Phone: 805-893-3087 | |
Mr. David Joseph Linzey, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 539 E Montecito St, Santa Barbara, CA 93103 Phone: 707-490-9100 | |
Mrs. Jamie Veronica Considine, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 215 Pesetas Ln, Santa Barbara, CA 93110 Phone: 805-563-6110 | |
Raelyn Nicole Hamman, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 612 Meigs Rd, Santa Barbara, CA 93109 Phone: 408-202-4130 |